West Lothian, United Kingdom

Keneth Davies

This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp + Dohme B.v.. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keneth Davies. Retrieved from https://idiyas.com/inventor/keneth-davies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Keneth Davies: Innovator in Tricyclic Heterocyclic Derivatives

Introduction

Keneth Davies is a notable inventor based in West Lothian, GB. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on tricyclic heterocyclic derivatives. His research focuses on developing compounds that can be used in the treatment of various serotonin-mediated disorders.

Latest Patents

Keneth Davies holds a patent for "Tricyclic heterocyclic derivatives." This invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification. It also encompasses pharmaceutically acceptable salts or solvates of these derivatives. The patent further details pharmaceutical compositions that include these tricyclic heterocyclic derivatives and their therapeutic applications, particularly in treating or preventing disorders such as obesity.

Career Highlights

Keneth Davies is associated with Merck Sharp & Dohme B.V., a leading global healthcare company. His work at Merck has allowed him to contribute to the development of innovative pharmaceutical solutions that address critical health issues.

Collaborations

Throughout his career, Keneth has collaborated with esteemed colleagues, including Takao Kiyoi and Ashvinkumar Dhirubhai Mistry. These collaborations have enhanced the research and development of his patented inventions.

Conclusion

Keneth Davies is a prominent figure in the field of pharmaceutical innovation, with a focus on tricyclic heterocyclic derivatives. His contributions have the potential to impact the treatment of serotonin-mediated disorders significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…